

Supplementary Table 4. Quartiles of WC and BMI variability measures and risk of nephropathy after excluding those who developed nephropathic event in the first year and those who had serious adverse events in first 18 months of the study

Variable	Events	Incidence rate/ 10 person-yr	Model 1		Model 2 ²	
			HR (95% CI)	P value	HR (95% CI)	P value
WC (cVIM)						
Q1	490	0.9	Ref		Ref	
Q2	604	1.0	1.08 (0.94–1.24)	0.281	1.08 (0.94–1.24)	0.283
Q3	636	1.1	1.06 (0.88–1.28)	0.512	1.06 (0.88–1.29)	0.513
Q4	662	1.2	0.98 (0.76–1.26)	0.854	1.01 (0.78–1.31)	0.922
WC (ASV)						
Q1	502	0.9	Ref		Ref	
Q2	595	1.0	1.13 (0.98–1.30)	0.084	1.14 (0.99–1.31)	0.079
Q3	644	1.1	1.15 (0.95–1.38)	0.151	1.12 (0.93–1.36)	0.231
Q4	651	1.2	1.11 (0.86–1.43)	0.411	1.10 (0.85–1.41)	0.487
WC (CV)						
Q1	490	0.9	Ref		Ref	
Q2	603	1.0	1.08 (0.94–1.23)	0.302	1.08 (0.94–1.24)	0.298
Q3	635	1.1	1.06 (0.88–1.28)	0.531	1.06 (0.88–1.28)	0.548
Q4	664	1.2	0.98 (0.76–1.26)	0.857	1.01 (0.78–1.31)	0.941
WC (SD)						
Q1	485	0.9	Ref		Ref	
Q2	569	1.0	1.08 (0.94–1.24)	0.304	1.10 (0.95–1.26)	0.208
Q3	655	1.2	1.19 (0.99–1.44)	0.062	1.13 (0.94–1.37)	0.200
Q4	683	1.2	1.15 (0.89–1.48)	0.274	1.10 (0.85–1.43)	0.453
BMI (cVIM)						
Q1	483	0.9	Ref		Ref	
Q2	554	1.0	1.15 (1.00–1.33)	0.048	1.19 (1.03–1.37)	0.019
Q3	633	1.1	1.39 (1.15–1.68)	0.001	1.38 (1.14–1.67)	0.001
Q4	722	1.3	1.68 (1.31–2.15)	<0.001	1.71 (1.33–2.20)	<0.001
BMI (ASV)						
Q1	493	0.8	Ref		Ref	
Q2	564	1.0	1.24 (1.07–1.43)	0.003	1.23 (1.07–1.43)	0.004
Q3	632	1.1	1.56 (1.29–1.90)	<0.001	1.54 (1.27–1.88)	<0.001
Q4	703	1.3	2.03 (1.58–2.61)	<0.001	1.96 (1.52–2.53)	<0.001
BMI (CV)						
Q1	480	0.8	Ref		Ref	
Q2	557	1.0	1.15 (1.00–1.33)	0.049	1.15 (1.00–1.33)	0.055
Q3	621	1.1	1.34 (1.11–1.62)	0.002	1.35 (1.11–1.63)	0.002
Q4	734	1.3	1.68 (1.31–2.16)	<0.001	1.65 (1.28–2.12)	<0.001
BMI (SD)						
Q1	467	0.8	Ref		Ref	
Q2	550	0.9	1.20 (1.04–1.39)	0.013	1.20 (1.04–1.39)	0.014
Q3	640	1.1	1.50 (1.24–1.81)	<0.001	1.49 (1.22–1.80)	<0.001
Q4	735	1.3	1.88 (1.46–2.42)	<0.001	1.85 (1.43–2.39)	<0.001

Model 1: unadjusted model; Model 2²: Adjusted for age, sex, race, duration of diabetes, blood pressure (BP) vs. lipid treatment arm, systolic BP, diastolic BP, low density lipoprotein, high density lipoprotein, glycosylated hemoglobin, antihypertensive, cardiovascular disease history, estimated glomerular filtration rate, urinary albumin creatinine ratio, and baseline BMI (or WC).

WC, waist circumference; BMI, body mass index; HR, hazard ratio; CI, confidence interval; cVIM, corrected variability independent of mean; ASV, average successive variability; CV, coefficient of variation; SD, standard deviation.